SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in […]
